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ABSTRACT 
 
Angiogenesis, a key step in many physiological and 
pathological processes, involves proteolysis of the extracellular 
matrix. To study the role of two enzymatic families, serine-
proteases and matrix metalloproteases in angiogenesis, we have 
adapted to the mouse, the aortic ring assay initially developed 
in the rat. The use of deficient mice allowed us to demonstrate 
that PAI-1 is essential for angiogenesis while the absence of an 
MMP, MMP-11, did not affect vessel sprouting. We report 
here that this model is attractive to elucidate the cellular and 
molecular mechanisms of angiogenesis, to identify, 
characterise or screen “pro- or anti-angiogenic agents that 
could be used for the treatment of angiogenesis-dependent 
diseases.  Approaches include using recombinant proteins, 
synthetic molecules and adenovirus-mediated gene transfer. 
 
INTRODUCTION 
 
Angiogenesis i.e. the sprouting of new blood vessels from pre-
existing vessels is an essential feature of tissue remodeling 
associated with at least wound healing, solid tumour 
development, proliferative retinopathies and rheumatoid 
arthritis. Extensive interest has been generated to elucidate the 
cellular and molecular mechanisms involved in the angiogenic 
process. Different in vivo and in vitro assays have been used so 
far in order to understand the development of the vascular 
system, and to screen angiogenic activators and inhibitors. 
Commonly used in vivo models of angiogenesis include the 
chorioallantoïc membrane of the chick embryo (CAM assay), 
the rabbit cornea, the hamster cheek pouch (1) and the Matrigel 
implant assay (2,3). Despite the relevance of these in vivo 
assays, systemic inflammatory reactions can lead to 
interferences that hamper their use for the study of 
angiogenesis regulation.  In vitro cultures of isolated 
endothelial cells are also useful to study the formation of 
microvessels but mimic only partially the vascular wall and 
paracrine interactions between endothelial cells and 
perivascular cells such as pericytes, smooth muscle cells or 
fibroblasts which are obviously not taken into account in these 
models. Nicosia and Ottinetti (4) demonstrated that rat aorta 
rings reproducibly generate microvessel outgrowths in fibrin or 
collagen gels, and provide a sensitive assay for the study of 
angiogenic agonists and antagonists in a chemically defined 
environment. This system bridges thus the gap between in vitro 
and in vivo models.  
 
Recently, the generation of transgenic mice allowed to study 
the impact of gain or loss of function for targeted molecules in 
various physiological and pathological situations. Genetically 
altered mice have proven to be valuable tools to study 
numerous diseases (5,6) and have revealed unanticipated roles 
for previously characterized proteins involved in angiogenesis 
(7,8). Paradoxically, αvβ3 and αvβ5 integrins (7) have been 
proposed as anti-angiogenic agents, whereas the plasminogen Masson et al.    
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activator inhibitor PAI-1 has been described as a pro-
angiogenic molecule (8,9). These recent findings emphasize 
the interest of in vitro angiogenic models to gain insight into 
the molecular mechanisms of angiogenesis. In this context, we 
have now adapted to the transgenic mouse, the aortic ring assay 
initially developed in the rat (4).  We focused our interest on 
two enzymatic systems (matrix metalloproteinases or MMPs, 
and serine-proteases) which play a central role during 
angiogenesis. These two proteolytic systems control 
angiogenesis in a cooperate manner by remodeling the 
extracellular matrix, thereby facilitating endothelial cell 
migration as well as by releasing matrix-bound angiogenic 
factors, cleaving cell surface molecules and generating 
angiogenic factors (10,11). 
While the inhibitor PAI-1 appears as an essential element for 
angiogenesis (8,9,12,13), deficiency in MMP-11 does not 
affect vessel outgrowth. We demonstrate here the possibility to 
transduce anti-angiogenic gene into aortic rings by adenovirus.  
 
MATERIALS AND METHODS 
 
Genetically modified mice 
Homozygous PAI-1
-/- deficient mice and their corresponding 
wild type (WT) with a mixed genetic background of 87.5% 
C57BL6 and 12.5% 129 SV/SL strain were generated as 
described previously (8). MMP-11
-/- and their corresponding 
wild type mice with the same genetic background (129 
SV/BL6 50/50) were kindly provided by M-C Rio (IGBMC, 
Strasbourg, France) (14). Mice between 8 and 12 weeks of age 
of both sexes were used for experiments.  
 
Preparation of the three-dimensional aortic ring 
cultures 
 
Angiogenesis was studied by culturing rings of mouse aorta in 
three-dimensional collagen gels with some modifications of the 
method originally reported for the rat aorta (4). Thoracic aortas 
were removed from mice sacrificed by cervical dislocation and 
immediately transferred to a culture dish containing ice-cold 
serum-free Minimum Essential Medium (MEM, Life 
Technologies Ltd., Paisley, Scotland). The peri-aortic 
fibroadipose tissue was carefully removed with fine 
microdissecting forceps and iridectomy scissors paying special 
attention not to damage the aortic wall. One millimeter long 
aortic rings (approximately 15 per aorta) were sectioned and 
extensively rinsed in 5 consecutive washes of MEM. Ring-
shaped explants of mouse aorta were then embedded in a rat 
tail interstitial collagen gel (1.5 mg/ml) (15) prepared by 
mixing 7.5 volumes of 2 mg/ml collagen (Collagen R, Serva, 
Heidelberg, Germany), 1 volume of 10 x MEM, 1.5 volume of 
NaHCO3 (15.6mg/ml) and approximately 0.1 volume of 1M 
NaOH to adjust the pH to 7.4. The collagen gels containing the 
aortic rings were polymerized in cylindrical agarose wells 
prepared as previously described (4) and kept in triplicate at 
37°C in 60 mm diameter Petri dishes (bacteriological 
polystyrene, Falcon, Becton Dickinson, Lincoln Park, New 
Jersey). Each dish contained 6 ml of MCDB131 (Life 
technologies Ltd., Paisley, Scotland) supplemented with 25 
mM NaHCO3, 2.5% mouse serum, 1% glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin. The cultures were kept 
at 37°C in a humidified environment for a week and examined 
every second day with an Olympus microscope at appropriate 
magnification. 
 
Quantification of angiogenesis 
 
To perform image analysis, all images must be taken under the 
same observation condition (light, contrast, magnification). In 
this case, processing parameters are fixed once for ever, and 
image processing became completely automatic. 
 
Image analysis was performed on a Sun SPARC30 workstation 
with the software «  Visilog 5.0  » from Noesis. We used an 
improved computer-assisted image analysis (16) which allows 
automatic measurements of the geometrical and morphological 
parameters. After generation of binary image, the following 
automatic measurements were performed: the number of 
microvessels (Nv); the maximal microvessel length (Lmax), and 
the total number of branching in microvessels (Nb). 
 
Fluorescent staining of endothelial cells 
 
To stain endothelial cells prior to sectioning, rinsing and 
collagen embedding, aortas were incubated for 4 hours at 37°C 
in a solution of 10 µg/ml fluorescent acetylated low density 
lipoprotein (Dil-Ac-LDL, acetylated low density lipoprotein 
labeled with 1,1’-dioctadecyl-3,3, 3’,3’-
tetramethylindocarbocyanine perchlorate, Biomedical 
Technologies Inc., Stoughton, Massachussets), which is 
selectively taken up by endothelial cells without affecting their 
growth rate (17). Cultures were then examined by fluorescent 
microscopy using rhodamine excitation and emission filters.  
Adenovirus-mediated ATF cDNA transfer 
E1E3-deleted adenoviruses directing from the cytomegalovirus 
(CMV) immediate early promoter expressing the murine 
Amino-Terminal Fragment of urokinase (ATF) (AdATF) or 
Escherichia coli β-galactosidase (AdCMVβgal = AdLacZ) 
were propagated as described previously (18). Thoracic aortas 
were removed from C57BL/6 mice sacrificed by cervical 
dislocation and immediately transferred to a culture dish with 
cold serum-free MEM. The periaortic fibroadipose tissue was 
carefully removed and each aorta was cut in 2 equal pieces. 
Pieces of aortas were immediately exposed or not to 
recombinant adenoviruses at 5 x 10
9 plaque-forming units in 
0.5ml DMEM in 24-well plate at 37°C in 5% CO2 (2 pieces of 
aortas from 2 different mice/condition). After one day of Masson et al.    
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infection, aorta were cut in 1 mm-long explants that were 
extensively rinsed with DMEM, embedded in collagen gel, and 
cultured with 2.5% of autologous serum. After 6 days of 
culture, explants were examined by microscopy and image 
analysis was performed. To evaluate the efficiency of 
transduction, WT aortic explants were exposed to AdLacZ, 
cultured in WT serum for 6 days and fixed for 20 min with cold 
paraformaldehyde 1% after removing the agarose around the 
collagen gel. Aorta rings embedded in collagen were rinsed 3 
times quickly with PBS, then rinsed 3 times for 15 min with 
washing solution (PBS containing 2mM MgCl2, 0.02% Igepal 
CA-630 and 0.01% Na deoxycholate) and finally stained 
overnight at 37°C in the dark in washing solution containing 
5mM K3Fe(CN)6, 5mM K4Fe(CN)6.3H20 and 1mg/ml 5-bromo-
4-chloro-3-indolyl-β-D-galactopyranoside (X-gal; Sigma, St. 
Louis, MI).  
 
Statistical analysis 
Experiments including four explants per condition were 
repeated at least twice. Student’s t test was used to evaluate 
whether differences among groups were significant. Statistical 
significance was set at p<0.05. 
 
RESULTS AND DISCUSSION 
Adaptation of rat aortic ring assay to the mice 
 
 
Fig. 1A-B :  Microvessel outgrowth from mouse and rat 
aorta.  Photomicrographs showing the maximal angiogenic 
response of explants isolated either from WT mice (A) cultured 
in autologous serum (2.5% final concentration) or from rat (B) 
cultured in serum-free MCDB131. Bar, 500 µm. The two 
angiogenic responses follow the same shape but differ in their 
time course. Mouse and rat microvessel outgrowth reach their 
maximal value at day 6 and 10, respectively. Microvessels 
were quantified by computer assisted image analysis and 
plotted as a function of the number of days in culture. Nv, 
number of microvessels; Nb, number of branchings, Lmax, 
maximal microvessel length. n = 4; error bars = SEM. 
In order to exploit the recent development of transgenic mice, 
we have adapted to the mouse the rat aortic ring assay in 
collagen gel. In sharp contrast to the rat system, addition of 2.5 
% mouse serum to MCDB 131 medium was an absolute 
requisite for microvessel outgrowth from mouse aortic rings. 
Indeed, serum-free medium failed to support angiogenesis from 
mouse explants. In the presence of serum, only isolated and 
dispersed fibroblast-like cells migrated into the gel within the 
first 4 days of culture (lag phase). Subsequently, microvessel 
outgrowth arose from the edges of parental vessels (growth 
phase). The endothelial nature of spreading cells was 
demonstrated by incubating the aortic ring with Dil-Ac-LDL, 
which is taken up by endothelial cells. 
 
We have developed a computer-assisted method which allows 
the measurement of the number of vessels and branchings, as 
well as their maximal length (16). The initially linear sprouts of 
endothelial cells progressively branched, anastomosed and 
formed a microvascular network reaching a maximal 
complexity at day 6 (Fig. 1A). 
 
In addition to this difference of microvessel sprouting kinetic 
observed between the two species systems, one should note 
that the highest number of microvessels was observed with rat 
aortic rings as compared to the mouse ones (52 + 3 versus 27 + 
2, respectively) (Fig. 1A and B). 
 
The advantage of the rat aortic system is that cultures can be 
maintained in the absence of serum, in a more chemically 
defined environment allowing for the evaluation of pro- or 
anti-angiogenic compounds (4,16,19). Our attempts to culture 
mouse aortic rings in defined medium supplemented with EGF, 
bFGF (EGM-2 BulletKit, Biowhittaker, Belgium) were 
unsuccessful. The main interest of the mouse system is to 
exploit the recent generation of transgenic mice and to study 
the consequence of deficiencies, mutations and conditional 
expression of gene products. 
 
Relevance of the mouse aortic ring assay to study 
the impact of the gene product deficiency on 
angiogenesis 
 
Endothelial cell migration requires extracellular matrix 
proteolysis, which involves at least two matrix-degrading Masson et al.    
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proteases, the plasminogen activator (PA)/plasmin system and 
the matrix metalloproteinase (MMP) family acting in a 
concerted manner (10). We recently demonstrated the key role 
played by the plasminogen activator inhibitor type-1 (PAI-1) 
during tumour invasion and angiogenesis (8,9). Indeed, the 
lack of PAI-1 in host mice prevented the local invasion and 
vascularization of tumours induced by malignant keratinocytes 
transplantation. In order to evaluate the relevance of the mouse 
aortic ring assay to study the functions of PAI-1, aortic 
explants resected from PAI-1-deficient mice or from their 
corresponding wild type (WT) were embedded in collagen gels 
in the presence of autologous serum. In contrast to the WT 
aortic rings from which microvessels spread out (Fig. 2A), no 
angiogenic response was observed from PAI-1 -/- aortic 
explants (Fig. 2B). The addition of recombinant PAI-1 used at 
10 ng/ml corresponding to physiological concentration in the 
plasma, led to a partial restoration of neovessel formation from 
PAI-1 -/- rings (Fig. 2C) (12). 
 
These data emphasize the central role of PAI-1 played during 
angiogenesis and confirm the data previously obtained in vivo 
(8,12,13). We next extended our study to MMP-11, which has 
been reported to influence the early steps of tumour 
progression. Indeed, MMP-11 expression promoted the in vivo 
tumour take (20) and its deficiency was associated with a 
reduction in tumour development (14). Several MMPs have 
been reported to play an important role in the early events of 
cancer progression such as angiogenesis (11,21,22).  
 
 
Fig. 2A-E: Angiogenesis is impaired in PAI-1 
-/- mice and 
restored by exogenous rPAI-1, while MMP-11 deficiency 
does not affect vessel outgrowth. Neovessel formation was 
compared in collagen-embedded explants isolated from WT 
(A,D), PAI-1
-/-(B) and MMP-11
-/-(E) mice (bar = 250 µm). 
Aortic rings were cultured for 6 days in autologous serum. In 
contrast to WT aortic ring (A), microvessel outgrowth was 
absent in PAI-1
-/-  aortic explants (B) whereas isolated 
fibroblast-like cells were still present. The addition of 10 ng/ml 
recombinant PAI-1 corresponding to plasmatic concentration, 
led to a partial restoration of neovessel formation from PAI-1
-/- 
rings (C). MMP-11 deficiency did not affect angiogenesis (D, 
E). The arrows delineate capillary outgrowth. 
 
However, so far no data suggest the direct implication of 
MMP-11 during tumoral angiogenesis. In accordance to this, 
we clearly demonstrate here that MMP-11-deficiency failed to 
affect angiogenesis in the aortic ring assay (Fig. 2 D,E). 
Adenoviruses-mediated transfer of cDNA into 
mouse aortic rings  
 
We next addressed the possibility to deliver and screen pro- or 
anti-angiogenic agents by using adenoviral vectors, which 
induce a prolonged gene expression. To attest the adenoviral 
transduction efficiency, mice aorta were incubated, before 
embedding into the collagen gel, with recombinant 
adenoviruses bearing the lacZ gene coding for beta-
galactosidase (Ad.LacZ). Both endothelial cells and fibroblast-
like cells expressed the transgene throughout the study. 
Interestingly, gene transduction did not affect the angiogenic 
response (Fig. 3). 
 
 
Fig. 3: Microvessel quantification of mouse aortic rings 
after adenoviral infection. Mouse aortic rings prepared from 
dA d d A d A l dMasson et al.    
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aorta exposed or not to AdLacZ and AdATF were cultured 
during 7 days. (A) Infection by AdLacZ demonstrated that both 
branched microvessels and individual fibroblast-like cells were 
infected by virus and expressed the viral transgene for the 
duration of the experiment (bar = 100µm). (B) Pictures of aorta 
explants were captured from optical microscopy: non infected 
(left); infected with AdLacZ (middle) or AdATF (right, bar = 
250µm). Image analysis was performed to quantify the number 
and the maximal length of microvessels. These two parameters 
are markedly inhibited by AdATF. Lmax = maximal microvessel 
length. Error bars = SEM. 
 
A large body of evidence validates uPA receptor (uPAR) as a 
target for cancer therapy. Disruption of the interaction of uPA 
with uPAR by derivatives of uPA has been shown to reduce 
tumour growth (23). Li et al. have used an adenoviral vector to 
deliver and express in vivo the murine uPAR-binding domain 
of uPA (uPA amino terminal fragment or ATF) (18). 
Intratumoral injection of these adenovirus into pre-established 
human or murine tumours arrested tumour growth and 
vascularization. Accordingly, incubation of aorta with 
recombinant adenovirus expressing murine ATF (AdATF) 
drastically inhibited the microvessel outgrowth (Fig. 3). These 
data confirm the interest of inhibiting uPA-uPAR interaction 
with ATF to counteract angiogenesis, and demonstrate that 
gene transfer in the aortic ring assay allows to test the possible 
therapeutic use of gene products for gene therapy. 
Altogether our study demonstrates the adequacy of the mouse 
aortic ring assay to identify, characterise and screen pro- or 
anti-angiogenic agents which could be used for the treatment of 
angiogenesis-dependant diseases. 
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PROTOCOLS 
 
A. Preparation of agarose wells. 
 
1. Solubilize 1.5g Agarose VII (Sigma, Belgium), in 100 ml MilliQ water and autoclave it (50 min., 1 bar). 
2. Run 30 ml of agarose in each sterile 10 mm tissue culture Petri dish (Falcon). 
3. After agarose polymerization, punch rings with 17 mm puncher first and then a 10 mm one.  
4. Remove the center of the rings and discard it. 
5. Grip the ring at its edge with a bowed spatula and lift it up. Place it upside down in a 60 mm Petri dish (bacterial cultures, Nunc). 
6. Place 3 rings per dish. 
 
B. Serum preparation. 
 
1. Sacrifice the mouse by cervical dislocation. 
2. Make a vertical midline section of the thorax. 
3. Use a pair of scissors to open the heart. 
4. Collect as much blood as possible with a sterile Pasteur pipette. 
5. Transfer blood to a sterile tube with Clot activator. 
6. Leave sample at room temperature for 10-15 min. 
7. Centrifuge at 3000 RPM, 5 min. at room temperature. 
8. Set sample on ice until use. 
 
C. Removal of the aorta from the mouse. 
 
1. Grab the aorta with the forceps and dissect aorta free from the connective tissue with scissors. 
2. Cut the aorta at the level of arcus aortica. 
3. Transfer aorta to sterile serum-free medium {DMEM (Gibco BRL) with 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco 
BRL)}. 
 
D. Removal of periaortic fibroadipose tissue from the aorta. 
 
1. Place aorta on a sterile cork plate covered with aluminum foil and fix it with sterile needles. 
2. Remove carefully periaortic fibroadipose tissue. 
3. Avoid aorta to dry out by dripping serum-free medium over it. 
4. When aorta is clean, place it in another cell culture plate lid with serum-free medium. 
5. Cut the aorta with the blade of a scalpel in 1 mm-long rings (about 15 rings/aorta). 
6. Transfer the rings to ice cold serum-free medium in a 50 ml tube (Falcon). Masson et al.    
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7. At this step explants can be stored for until two hours. 
 
E. Preparation of collagen type I (at 4°C, in a sterile hood). 
 
1. Place on ice and in a sterile hood an autoclaved beaker with a magnet on it. 
2. Prepare collagen solution by mixing 7.5 volumes of 2 mg/ml collagen (Collagen R, Serva, Heidelberg, Germany), 1 volume of 
10 x MEM (as color indicator), 1.5 volumes of NaHCO3 (15.6mg/ml) and approximately 0.1 volume of 1M NaOH to adjust the pH 
to 7.4.  
 
F. Embedding of aortic rings in collagen type I. 
 
1. Take the 60 mm Petridish containing the 3 agarose rings (step A). 
2. Add 200 µl of Collagen type I (step E) and let it polymerize at 37°C for 10 min. 
3. Add 1 explant per agarose ring on top of the collagen I (on side) and then pour 200 µl of the collagen type I on top of it. 
4. Let it polymerise for 10 min at 37
oC. 
5. In each petri dish containing 3 agarose wells add 5.850 ml of MCDB131 (Life technologies Ltd., Paisley, Scotland) 
supplemented with 25 mM NaHCO3, 2.5% mouse serum (150µl) (step B), 1% glutamine, and P/S. 
6. Incubate at 37 
oC, 5% CO2 for 6 days. 